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Abstract
Observational studies suggested a link between bone disease and left ventricular (LV) dys-
function that may be pronounced in hyperparathyroid conditions. We therefore aimed to test
the hypothesis that circulating markers of bone turnover correlate with LV function in a
cohort of patients with primary hyperparathyroidism (pHPT). Cross-sectional data of 155
subjects with pHPT were analyzed who participated in the “Eplerenone in Primary Hyper-
parathyroidism” (EPATH) Trial. Multivariate linear regression analyses with LV ejection frac-
tion (LVEF, systolic function) or peak early transmitral filling velocity (e’, diastolic function)
as dependent variables and N-terminal propeptide of procollagen type 1 (P1NP), osteocal-
cin (OC), bone-specific alkaline phosphatase (BALP), or beta-crosslaps (CTX) as the
respective independent variable were performed. Analyses were additionally adjusted for
plasma parathyroid hormone, plasma calcium, age, sex, HbA1c, body mass index, mean
24-hours systolic blood pressure, smoking status, estimated glomerular filtration rate, anti-
hypertensive treatment, osteoporosis treatment, 25-hydroxy vitamin D and N-terminal pro-
brain B-type natriuretic peptide. Independent relationships were observed between P1NP
and LVEF (adjusted β-coefficient = 0.201, P = 0.035) and e’ (β = 0.188, P = 0.042), respec-
tively. OC (β = 0.192, P = 0.039) and BALP (β = 0.198, P = 0.030) were each independently
related with e’. CTX showed no correlations with LVEF or e’. In conclusion, high bone forma-
tion markers were independently and paradoxically related with better LV diastolic and,
partly, better systolic function, in the setting of pHPT. Potentially cardio-protective properties
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of stimulated bone formation in the context of hyperparathyroidism should be explored in
future studies.
Introduction
Left ventricular (LV) systolic and diastolic dysfunction account for high morbidity and mortal-
ity and often occur in concert with disturbances in bone metabolism. Accumulating evidence
suggests a direct link between bone disease and LV function that may be pronounced in pri-
mary hyperparathyroidism (pHPT). In a bone biopsy study conducted in patients with chronic
heart failure (CHF) the local bone environment showed evidence of dysregulated and catabolic
state that was correlated with circulating biomarkers of bone turnover [1]. In 60 CHF patients
bone mineral density was inversely related with parathyroid hormone (PTH) and an indepen-
dent predictor of a composite outcome of death, implantation of a LV assist device, or inotrope
dependency [2]. Vertebral fractures are present in up to 16% of chronic heart failure (CHF)
patients [3, 4] and the risk of hip fracture is almost doubled in CHF patients when compared
to patients without CHF [5]. Vice versa, Pfister and colleagues recently reported that low bone
mineral density (BMD) was an independent predictor of new-incident CHF in a large cohort
of apparently healthy subjects followed for a mean of 9.9 years, even after adjustment for car-
diovascular risk factors [6].
PHPT is a condition of autonomously and chronically elevated PTH [7]. Patients with
pHPT show biochemical features of stimulated bone turnover [8] and abnormal bone micro-
structure [9, 10] and this leads to an increased risk of osteoporosis and fractures [11]. Emerg-
ing evidence supports the role of high PTH as a novel risk factor for heart failure [12, 13]. In
fact, pHPT patients often present with alterations in LV function [14, 15], besides their altered
bone metabolism, and are exposed to an increased risk of cardiovascular mortality [16]. PHPT
may therefore constitute a suitable human model to study the potential crosslink between
bone turnover and LV function. Yet, studies in humans are completely lacking.
We therefore aimed to test the hypothesis that bone turnover markers are associated with
LV systolic and diastolic function in a cohort of pHPT patients.
Methods
Patients and setting
This research was approved by the Ethics Committee of the Medical University of Graz (# 24–
031 ex 11/12). All subjects provided written informed consent.
Cross-sectional data from screening participants for the single-center, randomized, pla-
cebo-controlled, double-blind, parallel-arm “Eplerenone in Primary Hyperparathyroidism”
(EPATH) Trial were used in the present analyses. The EPATH trial tested the effect of daily
eplerenone application over 8 weeks in comparison to placebo on PTH levels in subjects with
pHPT [17]. Further details on the study design and setting have been previously reported [17,
18]. Main inclusion criteria for trial participation were age of at least 18 years and informed
consent, main exclusion criteria were any acute illness or any disease with an estimated life
expectancy less than one year or ongoing radiation or chemotherapy. For the present analyses,
we included all participants with a biochemical diagnosis of pHPT (n = 155). All subjects pro-
vided written informed consent. The study was approved by the local ethics committee and
complies with the Good Clinical Practice (GCP) guidelines and the Declaration of Helsinki.
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Laboratory, echocardiography and ambulatory blood pressure
monitoring
Blood samplings were performed during the morning (07:00AM—11:00AM) after an over-
night fast. Patients remained in the seated position before blood sampling for at least 10 min-
utes. All samples were kept at room temperature before analyses, except for those that were
used to measure PTH which were kept at 4˚C. A pre-specified volume of blood samples was
centrifuged and filled into 1mL aliquots and frozen at -80˚C. Markers of osteoblast activity (N-
terminal propeptide of procollagen type 1 (P1NP), total osteocalcin [OC], bone-specific alka-
line phosphatase [BALP]) and osteoclast activity (beta-crosslaps [CTX]) were determined
from one time frozen serum on an IDS-iSYS multi-discipline automated system using
Enzyme-Linked Immunosorbent Assays (Immunodiagnostic Systems Ltd., Boldon, UK).
Intra- and interassay coefficients of variation (CV) are 3.2% to 9.6% and 5.5% to 9.5% for
P1NP, 1.3% to 2.2% and 2.7% to 5.1% for OC, 2.6% to 6.5% and 3.7% to 6.4% for BALP and
1.7% to 3.0% and 2.5% to 10.9% for CTX. PTH was measured immediately after blood sam-
pling on an Elecsys 2010 (Elecsys immunoassay analyzer, Cobas, Roche Diagnostics GmbH,
Mannheim, Germany) applying an ElectroChemiLuminescence ImmunoAssay (ECLIA). Nor-
mal range is 15–65 pg/ml (1.6–6.9 pmol/L), intra- and interassay CVs are 1.5% to 2.7% and
3.0% to 6.5%. Plasma calcium was adjusted for hypoalbuminemia as previously reported [19].
Other laboratory parameters were assessed using routine laboratory methods as previously
described [17].
Echocardiographic examinations were performed with a Vivid 7 or Vivid 9 (GE Healthcare,
Chalfont St Giles, UK), as previously reported [19]. All images and recorded loops were ana-
lyzed in a central core lab (Echocardiography CoreLab, Department of Cardiology, Medical
University of Graz, Graz, Austria) by a single investigator who was blinded to individual
participant data (EB). Tissue Doppler imaging was employed to measure peak early filling
velocities of the mitral septal and lateral ring (e’, in cm/s). Following international guidelines
averaged e’ was generated according to the formula e’average = (e’medial + e’lateral)/2 [20]. LV
ejection fraction (LVEF) was calculated by Simpson biplane method of disks [21].
A validated portable device for continuous ambulatory blood pressure monitoring (ABPM)
(Mobil-O-Graph, I.E.M. GmbH, Stolberg, Germany) was employed to execute the 24-hours
ABPM.
Primary hyperparathyroidism
Hypercalemic pHPT was defined as hypercalcemia (total serum albumin adjusted calcium >
2.55 mmol/L) and inappropriately high PTH of> 46 pg/mL at the study baseline visit [17, 22,
23]. Normocalcemic pHPT was defined as PTH> 65 pg/mL, albumin adjusted plasma cal-
cium above the median of the reference range (>2.35 mmol/L) and plasma ionized calcium
within normal ranges, in the absence of advanced chronic kidney disease (eGFR < = 40 mL/
min/m2) or 25-hydroxy vitamin D (25(OH)D) deficiency (25(OH)D < 20 ng/dL) as potential
causes for secondary hyperparathyroidism [17, 22–24].
Statistical methods
Assuming a correlation co-efficient of 0.225 lead to a sample size of 153 subjects to achieve a
power of 80% at a significance level of 5%.
Continuous variables are expressed as the mean +/- standard deviation (SD) or as the
median (interquartile range, IQR) as appropriate. Categorical variables are expressed as num-
bers (percentages). The distribution of continuous parameters and their residuals were
Bone turnover and ventricular function in primary hyperparathyroidism
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evaluated by test of Kolmogorov-Smirnov, kurtosis, skewness, concordance between the mean
and median, and visual inspection. Non-normally distributed variables were 10-logarithmized,
squared (only LVEF) or Ln-logarithmized (only CTX), as appropriate, before use in parametri-
cal procedures. Associations between bone turnover markers with PTH, calcium, LVEF and e’
were assessed using Pearson correlation analyses. In stepwise multivariate linear regression
models with each of the bone markers as a respective independent variable, model 1 included
as additional independent covariates PTH and calcium. In model 2, further adjustment was
made for parameters that are considered classical modifiers of either bone turnover or cardiac
function. These included age, sex, HbA1c, body mass index (BMI), mean 24-hours systolic
blood pressure (SBP), smoking status, estimated glomerular filtration rate (eGFR, CKDEPI),
ongoing antihypertensive treatment, ongoing osteoporosis treatment, serum 25(OH)D, and
N-terminal pro-brain B-type natriuretic peptide (NT-proBNP). Stepwise multivariate linear
regression models with LVEF or e’ as the respective dependent variable and P1NP, OC, BALP,
or CTX as a respective independent variable were performed. Further adjustments followed
model 1 and model 2 as described above. For all stepwise multivariate linear regression analy-
ses, a P-value < 0.05 was used for inclusion and a P-value > 0.1 was used for exclusion of
variables.
Normocalcemic pHPT may potentially differ from hypercalcemic pHPT with regard to an
interaction between bone turnover and LV function. Therefore, all multivariate linear regres-
sion analyses were repeated exclusively in subjects with normocalcemic and with hypercalce-
mic pHPT, respectively.
For statistical analyses we used SPSS 22.0 (SPSS, Inc, Chicago, IL). A two-sided P-value <
0.05 was considered statistically significant.
Results
Mean age was 67.0 +/- 10.6 years and 122 subjects (78.7%) were females. Median PTH was
99.1 pg/mL (81.5–124.6) and mean adjusted calcium was 2.63 +/- 0.14 mmol/L. PHPT was
hypercalcemic in 113 subjects (72.9%). Baseline characteristics are shown in Table 1.
Bone markers and PTH/calcium
In multivariate regression analyses (model 2), PTH was directly and independently correlated
with P1NP (adjusted β-coefficient = 0.210, P = 0.013), OC (β = 0.321, P = 0.001), BALP (β =
0.270, P = 0.002) and CTX (β = 0.378, P = 0.001). Calcium was directly and independently cor-
related with P1NP (β = 0.180, P = 0.036) and BALP (β = 0.182, P = 0.038), but not with OC
(β = 0.105, P = 0.210) and CTX (β = 0.065, P = 0.440). Details are shown in Table 2.
Bone markers and LV function
With adjustment for PTH and calcium (model 1), P1NP was independently related with e’
(β = 0.212, P = 0.021) and LVEF (β = 0.182, P = 0.043). OC was significantly related with e’
(β = 0.264, P = 0.004), but not with LVEF (β = 0.149, P = 0.100). BALP was significantly related
with e’ (β = 0.191, P = 0.042), but not with LVEF (β = 0.165, P = 0.072). CTX showed a signifi-
cant correlation with e’ (β = 0.217, P = 0.022), but not with LVEF (β = 0.121, P = 0.197).
After multivariate adjustment (model 2), P1NP remained an independent determinant of e’
(β = 0.188, P = 0.042) and LVEF (β = 0.201, P = 0.035). Both OC and BALP were indepen-
dently related with e’ (OC: β = 0.192, P = 0.039; BALP: β = 0.198, P = 0.030). CTX was neither
correlated with e’ (β = 0.146, P = 0.133) nor with LVEF (β = 0.102, P = 0.310). Detailed results
are shown in Table 3.
Bone turnover and ventricular function in primary hyperparathyroidism
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Hypercalcemic versus normocalcemic primary hyperparathyroidism
Multivariate regression analyses (model 2) were repeated exclusively in subjects with hypercal-
cemic pHPT (n = 113). P1NP did not significantly correlate with e’ (β = 0.196, P = 0.098) or
LVEF (β = 0.129, P = 0.261). OC and BALP were independently related with e’ (OC: β = 0.260,
P = 0.031; BALP: β = 0.221, P = 0.044), but not with LVEF (OC: β = 0.116, P = 0.328; BALP:
β = -0.025, P = 0.814). There was no correlation between CTX and e’ or LVEF, respectively.
None of the bone markers correlated with e’ or LVEF when analyses were restricted exclu-
sively to subjects with normocalcemic pHPT (n = 42).
Discussion
In a well-characterized and relatively large cohort of subjects with pHPT, circulating markers
of bone formation were independently related with e’ as a measure of LV diastolic function.
P1NP was also independently correlated with LVEF. These associations were independent of
potentially confounding parameters. Thus, our data provide novel evidence on a direct link
between bone formation and LV function in the setting of pHPT.
Clinical data on a link between bone turnover and LV function are sparse and longitudinal
studies reporting associations with cardiovascular outcome data have been inconsistent. In a
Table 1. Baseline characteristics of 155 subjects with primary hyperparathyroidism.
General Age, years 67.0 +/- 10.6
Females, n (%) 122 (78.7%)
Body mass index, kg/m2 27.8 +/- 5.0
Smokers, n (%) 59 (38.1%)
Estimated GFR, mL/min/1.73m2 76.9 +/- 16.4
Glycated hemoglobin A1C, mmol/mol 37.0 (35.0–40.0)
Total Cholesterol, mg/dL 203.0 +/- 42.3
Calcium metabolism Hypercalcemic pHPT, n (%) 113 (72.9%)
Parathyroid hormone (1–84), pg/mL 99.1 (81.5–124.6)
25-hydroxy vitamin D, ng/mL 34.3 +/- 11.4
Adjusted calcium, mmol/L 2.63 +/- 0.14
Phosphate, mg/dL 2.42 +/- 0.37
Bone P1NP, ng/mL 48.0 (31.2–71.3)
Bone-specific alkaline phosphatase, μg/mL 19.1 (14.7–25.8)
Osteocalcin, ng/mL 22.8 (16.0–35.1)
Beta-crosslaps, ng/mL 0.44 (0.23–0.71)




Cardiovascular Left ventricular ejection fraction, % 63.0 (59.0–67.7)
e’ (average), cm/s 7.1 +/- 2.3
Mean 24-hours SBP, mmHg 125.5 +/- 12.2
Mean 24-hours DBP, mmHg 76.4 +/- 8.6
Antihypertensive medication (yes/no), n (%) 83 (53.5%)
Parameters are expressed as mean +/- SD or median (interquartile range), as appropriate.
Abbreviations: GFR, glomerular filtration rate (CKD EPI); pHPT, primary hyperparathyroidism; RANKL, receptor activator of nuclear factor kappa-B ligand;
P1NP, procollagen type 1 amino-terminal propeptide; SBP, systolic blood pressure; DBP, diastolic blood pressure.
https://doi.org/10.1371/journal.pone.0173799.t001
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small cohort of 20 hypertensive patients without pHPT, higher P1NP was not associated with
echocardiographic parameters of diastolic dysfunction [25]. High CTX was consistently associ-
ated with increased cardiovascular mortality in clinical studies [26–28]. By contrast, longitudi-
nal studies on bone formation markers reported arbitrary results, with most showing an
inverse association between bone markers and mortality [26, 28, 29]. Only one study is avail-
able that aimed at examining potential effects of PTH application on LV function. These
authors analyzed the progress of levels of NT-proBNP in osteoporotic subjects one, three and
Table 2. Correlations between parathyroid hormone/calcium and markers of bone turnover in univariate and multivariate analyses.
Dependent variable Explanatory variable Pearson correlation
analysis
Multivariate linear regression analysis
Model 1 Model 2
r P β P β P
P1NP PTH 0.145 0.073 0.149 0.074 0.210 0.013
Calcium 0.299 0.001 0.268 0.002 0.179 0.035
OC PTH 0.271 0.001 0.298 0.001 0.321 0.001
Calcium 0.199 0.014 0.108 0.193 0.105 0.210
BALP PTH 0.259 0.001 0.236 0.004 0.270 0.002
Calcium 0.308 0.001 0.243 0.003 0.182 0.038
CTX PTH 0.339 0.001 0.318 0.001 0.378 0.001
Calcium 0.249 0.002 0.131 0.128 0.065 0.440
Model 1 includes calcium and parathyroid hormone as covariates. Model 2 additionally includes age, sex, HbA1c, body mass index, mean 24-hours systolic
blood pressure, smoking status, estimated glomerular filtration rate (CKDEPI), ongoing antihypertensive treatment, ongoing osteoporosis treatment,
25-hydroxy vitamin D, and N-terminal pro-brain B-type natriuretic peptide.
β represents adjusted regression coefficient.
Abbreviations: P1NP, N-terminal propeptide of procollagen type 1; OC, N-mid osteocalcin; BALP, bone-specific alkaline phosphatase; CTX, beta-crosslaps;
PTH, parathyroid hormone.
https://doi.org/10.1371/journal.pone.0173799.t002
Table 3. Correlations between markers of bone turnover and echocardiographic parameters of left ventricular function in univariate and multivari-
ate analyses.
Dependent variable Explanatory variable Pearson correlation
analysis
Multivariate linear regression analysis
Model 1 Model 2
r P β P β P
e‘ P1NP 0.190 0.021 0.212 0.021 0.188 0.042
OC 0.224 0.006 0.264 0.004 0.192 0.039
BALP 0.147 0.076 0.191 0.042 0.198 0.030
CTX 0.168 0.047 0.217 0.022 0.146 0.133
LVEF P1NP 0.077 0.347 0.182 0.043 0.201 0.035
OC 0.061 0.460 0.149 0.100 0.138 0.158
BALP 0.072 0.381 0.165 0.072 0.108 0.248
CTX 0.085 0.314 0.121 0.197 0.102 0.310
Model 1 includes calcium and parathyroid hormone as covariates. Model 2 additionally includes age, sex, HbA1c, body mass index, mean 24-hour systolic
blood pressure, smoking status, estimated glomerular filtration rate (CKDEPI), ongoing antihypertensive treatment, ongoing osteoporosis treatment,
25-hydroxy vitamin D, and N-terminal pro-brain B-type natriuretic peptide.
β represents adjusted regression coefficient.
Abbreviations: P1NP, N-terminal propeptide of procollagen type 1; OC, N-mid osteocalcin; BALP, bone-specific alkaline phosphatase; CTX, beta-crosslaps;
LVEF, left ventricular ejection fraction.
https://doi.org/10.1371/journal.pone.0173799.t003
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six months after initiation of treatment with PTH (1–34) and found no change in comparison
to baseline [30].
Bone formation markers were independently related with PTH levels in our cohort and cor-
relations between these markers and LV function were pronounced after adjustment for PTH
and calcium. Moreover, these associations were only present in subjects with hypercalcemic
disease. Our observations should therefore be regarded in the context of autonomously ele-
vated PTH. Besides skeletal impairment, alterations in LV function and an increased cardio-
vascular risk have been documented in pHPT, even in mild disease [14–16]. Epidemiological
studies suggested a mechanistic crosslink between bone and cardiac disease [1–6] and it is rea-
sonable to assume that this relationship could be pronounced in pHPT. Surprisingly, our data
rather point towards cardio-protective properties of stimulated bone formation. In that aspect
the emerging role of bone metabolism for endothelial functioning, systemic energy metabo-
lism and stem cell proliferation and mobilization may be of relevance. Recent studies have
provided evidence on a molecular crosstalk between bone forming and endothelial cells facili-
tating a close interweavement of endothelial function and bone turnover [31]. By promoting
the secretion of vascular endothelial growth factor (VEGF) and nitric oxide from endothelial
cells PTH is a stimulator of the bone-vascular axis in experimental settings [32, 33]. Some stud-
ies indicated that these PTH actions on bone and on the vasculature impose beneficial effects
to the cardiovascular system. In rats with induced myocardial infarction PTH application led
to mobilization of angiogenic progenitor cells from bone marrow and improved survival and
reduced infarct size compared to sham treatment, probably via promoting VEGF-mediated
cardiac neovascularization [34]. Also in humans, PTH administration was associated with
increases in circulating hematopoietic stem cells and an improvement in carotid intima-media
thickness [35, 36]. Patients with pHPT exhibited higher numbers of circulating bone marrow
derived progenitor cells compared to healthy controls, and increased VEGF levels [37]. It
could therefore be speculated that in pHPT high bone formation markers can be considered a
surrogate of preserved responsiveness of the bone-vascular axis to PTH.
Our observations could be explained by direct effects of osteoblast-derived hormones on
LV function. Particularly the role of OC for cardiovascular disease has recently received attrac-
tion. OC is secreted from osteoblasts, e.g. upon activation by PTH, and is increasingly consid-
ered to play a pivotal role in systemic energy metabolism. Low OC levels were associated with
chronic heart failure [38] and an increased risk of cardiovascular events [39]. Nevertheless,
potential direct effects of OC on cardiomyocytes remain unclear and should be addressed in
future research. Vice versa, LV function may have direct influence on bone formation. In fact,
implantation of a ventricular assist device in patients with CHF was associated with an increase
in P1NP suggesting that improvement in LV function may stimulate bone formation [40].
Several aspects of the present work can be considered as significant strengths. These include
the novelty aspect, as—to the best of our knowledge—no clinical study has yet examined a link
between bone turnover markers and LV function in pHPT. Correlations with LV diastolic
function were consistent using different formation markers and the relatively large sample size
enabled us to adjust comprehensively for important potentially confounding parameters.
Moreover, laboratory and echocardiographic parameters were measured prospectively and
under blinded and standardized conditions.
Our study is limited by its cross-sectional character, and no conclusions can be drawn on a
potential cause-effect relationship between bone formation and LV function. In addition, due
to the single-center design our results may not be applicable to other pHPT populations.
Despite the use of multivariate regression models residual confounding cannot be ruled out.
As a conclusion, circulating markers of bone formation were independently related with
LV diastolic function and, partly, with systolic function in a relatively large-sized cohort of
Bone turnover and ventricular function in primary hyperparathyroidism
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patients with pHPT. These data provide first clinical evidence on a direct link between bone
formation and LV function in pHPT. Potentially cardio-protective properties of stimulated
bone formation in the context of hyperparathyroidism and underlying mechanisms should be
explored in future studies.
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